JLPC(SH:600513)2020-04-24 16:00Financial Performance - Operating revenue for the period was ¥292,206,038.69, representing an 18.82% increase compared to the same period last year[5] - Net profit attributable to shareholders of the listed company was ¥19,136,150.82, up 14.75% year-on-year[5] - Basic earnings per share increased to ¥0.07, a rise of 16.67% compared to the previous year[5] - The company reported a profit of CNY 29,004,776.76 for Q1 2020, an increase of 43.41% from CNY 20,225,520.76 in Q1 2019, driven by increased revenue from subsidiaries[10] - Net profit for Q1 2020 was ¥23,299,869.68, representing a 38.1% increase from ¥16,855,374.13 in Q1 2019[24] - The total comprehensive income attributable to the parent company was CNY 19,136,150.82, compared to CNY 16,675,964.69 in the previous year, marking an increase of 14.73%[25] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,907,947,098.50, an increase of 0.97% compared to the end of the previous year[5] - Total liabilities decreased slightly to CNY 799,897,559.38 from CNY 805,571,326.13, indicating a focus on managing debt levels[16] - Total assets as of March 31, 2020, amounted to ¥1,486,052,722.93, compared to ¥1,396,244,221.29 at the end of 2019, indicating a growth of 6.4%[20] - Total liabilities as of March 31, 2020, were ¥579,879,358.19, an increase from ¥505,231,517.99 at the end of 2019, reflecting a rise of 14.7%[21] - Total current assets amounted to approximately 461.95 million, with cash and cash equivalents at 106.23 million[42] - Current liabilities were approximately 458.20 million, with short-term borrowings at 150.20 million[43] Shareholder Information - Net assets attributable to shareholders of the listed company amounted to ¥1,009,107,992.17, reflecting a growth of 2.01% year-on-year[5] - The total number of shareholders reached 50,130 at the end of the reporting period[9] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 36.76% of the shares[9] - Shareholders' equity totaled ¥906,173,364.74 as of March 31, 2020, compared to ¥891,012,703.30 at the end of 2019, marking a growth of 1.5%[21] Cash Flow - The net cash flow from operating activities was -¥4,973,937.14, showing an improvement from -¥38,824,627.79 in the same period last year[5] - The company reported a net cash outflow from operating activities of CNY -4,973,937.14, an improvement from CNY -38,824,627.79 in Q1 2019[32] - Cash and cash equivalents decreased to ¥96,227,802.57 from ¥106,229,661.72, a decline of 9.4%[19] - The net cash flow from financing activities improved to ¥27,152,365.87 in Q1 2020 from ¥9,674,958.33 in Q1 2019, reflecting a positive change in financing strategy[36] Research and Development - Research and development expenses rose to CNY 3,400,893.29 in Q1 2020, a 32.09% increase from CNY 2,574,720.32 in Q1 2019, indicating a focus on innovation[10] - Research and development expenses for Q1 2020 were ¥3,400,893.29, up from ¥2,574,720.32 in Q1 2019, indicating a growth of 32.0%[24] Government Subsidies - Government subsidies recognized in the current period amounted to ¥595,982.44[6] - The company received increased government subsidies, with other income rising to CNY 595,982.44 in Q1 2020, a 72.75% increase from CNY 345,000.00 in Q1 2019[10] Investment and Expenses - Investment losses increased to -CNY 246,802.74 in Q1 2020, compared to -CNY 138,188.96 in Q1 2019, indicating challenges in joint ventures and associates[10] - The company incurred financial expenses of CNY 1,978,822.78 in Q1 2020, significantly higher than CNY 322,454.43 in the same period last year[27] Inventory and Assets Management - The company reported a significant amount of inventory at approximately 66.24 million, indicating potential for future sales[42] - The company has ongoing construction projects valued at approximately 499.21 million, suggesting expansion efforts[43] - The company has a total of approximately 34.59 million in intangible assets, highlighting investments in intellectual property[43]